Editor's Note Coronary artery bypass graft (CABG) surgery and transcatheter aortic valve replacement (TAVR) generate the highest overall financial returns for US hospitals, despite not being the most profitable per procedure, according to a February 13 report in Cardiovascular Business. The article covers an analysis of Medicare data, published in…
Editor’s Note At the Society of Thoracic Surgeons (STS) annual meeting, experts urged cardiac surgeons to become more engaged in tricuspid valve treatment before transcatheter options gain too much traction according to a January 26 report in MedPage Today. With new transcatheter devices gaining FDA approval and the Centers for…
Editor's Note The largest scale analysis so far available comparing surgical aortic valve replacement (SAVR) to longer-term percutaneous devices for transcatheter aortic valve replacement (TAVR) supports the comparable long-term safety and efficacy of the latter procedure. According to a May 15 report in Medical Xpress, the findings raise important considerations for valve…
Editor's Note Patients with severe cases of tricuspid regurgitation (in which a critical heart valve fails to close properly) now have a new treatment option thanks to the recent US Food and Drug Administration (FDA) approval of the ENVOQUE tricuspid valve replacement system, according to a February 2 press release…
Editor's Note This study by researchers at Cedars-Sinai Medical Center, Los Angeles, finds that redo transcatheter aortic valve replacement (TAVR) procedures are both safe and effective. Of 350,591 patients in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry who underwent TAVR with balloon-expandable valves between November…